跳至主要内容
临床试验/EUCTR2021-002533-42-Outside-EU/EEA
EUCTR2021-002533-42-Outside-EU/EEA进行中(未招募)1 期

Oral Desensitization to Peanut in Peanut-AllergicChildren and Adults Using Characterized PeanutAllergen (CPNA) Peanut Oral Immunotherapy (OIT)Safety Follow-On Study

Aimmune Therapeutics, Inc.0 个研究点开始时间: 2021年12月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Completion of study ARC001
  • Written informed consent from subject and/or parent/guardian
  • Written assent from all subjects as appropriate
  • Use of birth control for females of child-bearing potential
  • No change in the status of any longitudinally applicable ARC001
  • inclusion criteria
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 50
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 5
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Early termination from ARC001
  • For former active AR101 (CPNA) treatment subjects from ARC001
  • (Group 2), failure to tolerate with no or mild symptoms 300 mg of peanut
  • protein in their ARC001 exit DBPCFC
  • Pregnancy or lactation
  • For former placebo subjects from ARC001 (Group 1), a lapse in dosing of
  • more than 10 days from completion of ARC001
  • Change in the status of any longitudinally applicable ARC001 exclusion criteria

研究者

相似试验

Peanut Allergy Study | 临床试验